Overview

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Status:
Terminated

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

- The purpose of the Phase I portion of this study is to evaluate the safety of this combination of medications and to determine the appropriate dose of VNP40101M to be used in combination with infusional cytarabine (araC) in elderly patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). - The purpose of the Phase II portion of the study is to evaluate the effectiveness (overall response rate) for patients treated with VNP40101M and infusional cytarabine induction therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Viron Therapeutics Inc
Weill Medical College of Cornell University

Collaborator:

Vion Pharmaceuticals

Treatments:

Antiemetics
Cytarabine